

# Alvimopan Shared System REMS Program

The requirements of the shared system REMS for alvimopan apply as of the date of full approval of the first abbreviated new drug application (ANDA) referencing Entereg (alvimopan).

## I. Administrative Information

Initial Shared System REMS Approval: 12/2019

## II. REMS Goal

The goal of the Alvimopan REMS Program is to mitigate the potential risk of myocardial infarction by:

1. Ensuring that alvimopan is used only for short-term use (no more than 15 doses) in a hospital inpatient setting

## III. REMS Requirements

**Alvimopan Applicants must ensure that healthcare settings and wholesalers-distributors comply with the following requirements:**

### 1. Healthcare settings that dispense alvimopan must:

---

To become certified to dispense	<ol style="list-style-type: none"><li>1. Have a pharmacy in an inpatient hospital that performs bowel resection surgery.</li><li>2. Designate an authorized representative to carry out the certification process and oversee implementation and compliance with the REMS Program on behalf of the hospital pharmacy.</li><li>3. Have the authorized representative review the <a href="#">Alvimopan REMS Kit</a>.</li><li>4. Have the authorized representative enroll in the Alvimopan REMS Program by completing the <a href="#">Hospital Pharmacy Enrollment</a> Form and submitting it to the REMS Program.</li><li>5. Train all relevant staff involved in prescribing, dispensing, or administering on safe use of alvimopan using the <a href="#">Alvimopan REMS Kit</a> materials.</li><li>6. Establish processes and procedures to verify no more than 15 doses are dispensed to the patient.</li></ol>
Before dispensing	<ol style="list-style-type: none"><li>7. Verify the patient receives no more than 15 doses through the processes and procedures established as a requirement of the REMS Program.</li></ol>

---

---

## 1. Healthcare settings that dispense alvimopan must:

---

- |              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| At all times | <ol style="list-style-type: none"><li>8. Not dispense alvimopan for outpatient use.</li><li>9. Not distribute, transfer, loan, or sell alvimopan, except to certified healthcare settings.</li><li>10. Re-certify in the Alvimopan REMS if the authorized representative changes.</li><li>11. Comply with audits carried out by alvimopan applicants or a third party acting on behalf of the applicants to ensure that all processes and procedures are in place and are being followed</li></ol> |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
- 

## 2. Wholesalers-Distributors that distribute alvimopan must:

---

- |                          |                                                                                                                                                                                                                                                                                                                                                         |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To be able to distribute | <ol style="list-style-type: none"><li>1. Establish processes and procedures to ensure that the drug is distributed only to certified healthcare settings.</li><li>2. Train all relevant staff involved in distributing alvimopan on REMS program requirements.</li></ol>                                                                                |
| At all times             | <ol style="list-style-type: none"><li>3. Distribute only to certified healthcare settings.</li><li>4. Maintain records of drug distribution.</li><li>5. Comply with audits carried out by the applicants or a third party acting on behalf of the applicants to ensure that all processes and procedures are in place and are being followed.</li></ol> |
- 

### **Alvimopan Applicants must provide training materials to healthcare settings that dispense alvimopan.**

The training includes the following: [Alvimopan REMS Program Kit](#) which includes the [Alvimopan REMS Program Overview](#), [Dear Healthcare Provider Letter](#), [Prescriber and Pharmacist Information Brochure](#) and [Hospital Pharmacy Enrollment Form](#). The training materials must be available in hard copy and online.

### **To support REMS Program operations, Alvimopan Applicants must:**

1. Establish and maintain a REMS Program website, [www.alvimopanREMS.com](http://www.alvimopanREMS.com). The REMS Program website must include the capability to complete hospital pharmacy certification and the option to print the Prescribing Information and REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS Program website. The REMS Program website must not link back to the promotional product website(s).
2. Make the REMS Program website fully operational and all REMS materials available through the website and coordinating/call center.
3. Establish and maintain a REMS Program coordinating/call center for REMS participants at [1-800 278 0340].
4. Establish and maintain a validated, secure database of all REMS participants who are enrolled and/or certified in the Alvimopan REMS Program.
5. Ensure hospital pharmacies are able to enroll in the Alvimopan REMS by fax and online.
6. Provide [Alvimopan REMS Kit](#) including an [Alvimopan REMS Program Overview](#), [Dear Healthcare Provider Letter](#), [Prescriber and Pharmacist Information Brochure](#) and [Hospital Pharmacy Enrollment Form](#), and the Prescribing Information to REMS participants who (1) attempt to dispense alvimopan and are not yet certified or (2) inquire about how to become certified.
7. Maintain a process to ensure that healthcare settings that want to become certified have a pharmacy in an inpatient hospital that performs bowel resection surgeries.

**To ensure REMS participants' compliance with the REMS Program, the Alvimopan Applicants must:**

8. Verify that the authorized representative's name and contact information correspond to those of the current designated authorized representative for the hospital pharmacy. If different, the hospital pharmacy must be required to re-certify with a new authorized representative before distribution of alvimopan from the wholesaler/distributor resumes.
9. Maintain adequate records to demonstrate that REMS requirements have been met, including, but not limited to records of: alvimopan distribution and dispensing; certification of hospital pharmacies; and audits of REMS vendors. These records must be readily available for FDA inspections.
10. Establish a plan for addressing noncompliance with REMS Program requirements.
11. Monitor hospital pharmacies on an ongoing basis to ensure the requirements of the REMS are being met. Take corrective action if non-compliance is identified, including de-certification.
12. Audit hospital pharmacies, in accordance with the audit plan, no later than 90 calendar days after they become certified, to ensure that all REMS processes and procedures are in place, functioning, and support the REMS Program requirements.
13. Take reasonable steps to improve implementation of and compliance with the requirements in the Alvimopan REMS Program based on monitoring and evaluation of the Alvimopan REMS Program.

## **IV. REMS Assessment Timetable**

Alvimopan NDA Applicants must submit REMS Assessments to FDA at 12 months following initial REMS approval, then annually, thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Alvimopan NDA Applicants must submit each assessment so that it will be received by the FDA on or before the due date.

## **V. REMS Materials**

The following materials are part of the Alvimopan REMS Program:

### **Enrollment Form**

1. [Hospital Pharmacy Enrollment Form](#)

### **Training and Educational Materials**

2. [REMS Program Overview](#)
3. [Dear Healthcare Provider Letter](#)
4. [Prescriber and Pharmacist Information Brochure](#)

### **Other Materials**

5. [REMS Program website](#)

# Alvimopan REMS Hospital Pharmacy Enrollment Form

**Instructions:** Alvimopan is only available through the Alvimopan Risk Evaluation and Mitigation Strategies (REMS). Hospital pharmacies that dispense alvimopan, must become certified in the REMS.

**To become certified to dispense alvimopan, your pharmacy must be in an inpatient hospital that performs bowel resection surgery.**

The Alvimopan REMS was developed to ensure that alvimopan is administered only short-term in inpatient hospital settings and for no more than 15 doses.

## **Authorized Representative Responsibilities**

**This hospital pharmacy acknowledges that:**

- The Alvimopan REMS Kit has been received by the hospital and education on the benefits and risks of alvimopan have been provided to the healthcare providers who are responsible for prescribing, dispensing, or administration of alvimopan
- The authorized representative understands the risks and benefits of alvimopan and has read the materials in the Alvimopan REMS Kit before alvimopan is dispensed
- The certified hospital pharmacy has policies and procedures in place to limit the use of alvimopan to no more than 15 doses per patient for administration in the hospital inpatient setting only
- The certified hospital pharmacy will not dispense alvimopan for outpatient use and will not transfer alvimopan to any hospital pharmacy not enrolled with the Alvimopan REMS
- The certified hospital pharmacy must re-certify in the program if the authorized representative changes and must resubmit this Hospital Pharmacy Enrollment Form

\*Hospital Name \_\_\_\_\_  
\*Hospital DEA# \_\_\_\_\_  
\_\_\_\_\_  
Hospital Industry Number \_\_\_\_\_  
\*Authorized Signatory First Name \_\_\_\_\_ \*Last Name \_\_\_\_\_  
\*Title  Hospital Pharmacist  
(must check one)  Representative of P&T Committee \_\_\_\_\_  
(insert title)  
\*E-mail Address \_\_\_\_\_  
\*Pharmacy Phone \_\_\_\_\_ \*Pharmacy Fax \_\_\_\_\_  
\*Hospital Ship-to Address \_\_\_\_\_  
\*City \_\_\_\_\_ \*State \_\_\_\_\_ \*ZIP Code \_\_\_\_\_  
Please check one:  New Enrollment  Update to Existing Enrollment  
\*Denotes mandatory fields to complete

I confirm that the information above is correct.

I understand that this information will be used by the Alvimopan REMS to verify the hospital performs bowel resection surgeries and to confirm eligibility to receive alvimopan.

I understand that this information may be shared with others working with the Alvimopan REMS, other hospitals enrolled in the Alvimopan REMS, and may be shared with government agencies.

I understand the certified hospital pharmacy must comply with audits to ensure that all processes and procedures are in place and are being followed.

Signature \_\_\_\_\_ Date \_\_\_\_\_

**To submit via fax:** Sign and fax to 1-800-278-1365.

**To submit via email:** Sign, scan, and email to [enroll@alvimopanREMS.com](mailto:enroll@alvimopanREMS.com).

After verification of eligibility, a confirmation will be provided to you, **via e-mail**. If you have any questions,

please contact the Alvimopan REMS at 1-800-278-0340 or visit [www.alvimopanREMS.com](http://www.alvimopanREMS.com).

**NOTE: If you have multiple shipping sites, please complete a separate registration for each ship site with an accompanying DEA number.**

# Alvimopan REMS Program Overview

## **What is the Alvimopan REMS?**

This **R**isk **E**valuation and **M**itigation **S**trategy (REMS) is a strategy to mitigate the potential risk of myocardial infarction associated with long-term use of alvimopan.

The (REMS) is required by the Food and Drug Administration (FDA) to ensure that the benefits of alvimopan outweigh this potential risk by informing/reminding healthcare practitioners that alvimopan should only be used short-term (no more than 15 doses) and in a hospital inpatient setting.

On 12/19/2019, the FDA approved the Alvimopan REMS, which replaces the E.A.S.E.® ENTEREG® REMS Program.

## **How does the Alvimopan REMS work?**

Hospital pharmacies that dispense alvimopan must become certified in the REMS.

**To become certified to dispense alvimopan, your pharmacy must be in an inpatient hospital that performs bowel resection surgery.**

## **What are the requirements of the Alvimopan REMS?**

The Program requires that an authorized representative designated by the hospital pharmacy attests that:

- The Alvimopan REMS Kit been received by the hospital and that all healthcare providers who are responsible for prescribing, dispensing, or administering alvimopan are educated on the benefits and risks of alvimopan
- The authorized representative understands the risks and benefits of alvimopan and has read the materials in the Alvimopan REMS Kit before alvimopan is dispensed.
- The certified hospital pharmacy has policies and procedures in place to limit the use of alvimopan to no more than 15 doses per patient for administration in the hospital inpatient setting only
- The certified hospital pharmacy will not dispense alvimopan for outpatient use and will not transfer alvimopan to any hospital pharmacy not enrolled with the Alvimopan REMS
- The certified hospital pharmacy must re-certify in the program if the authorized representative changes

The Alvimopan REMS Kit includes all REMS materials and a copy of the alvimopan Prescribing Information.

## **For More Information:**

In addition, all REMS materials are available on the Alvimopan REMS Website at [www.alvimopanREMS.com](http://www.alvimopanREMS.com).

## **Adverse Events Reporting**

To report suspected adverse reactions contact:

**Approved for hospital use only**

- Alvimopan REMS Program at 1-800-278-0340.
- FDA at 1-800-FDA-1088 (1-800-332-1088) or at [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**Please see [alvimopanREMS.com](http://alvimopanREMS.com) for links to the complete Prescribing Information.**

# **IMPORTANT DRUG WARNING**

## **Alvimopan REMS Dear Healthcare Provider Letter**

**Subject:** Potential risk of myocardial Infarction observed with long-term use of Alvimopan

**Prescriber Action:** Alvimopan should only be used short-term (no more than 15 doses) and in a hospital inpatient-setting

### **Dear Healthcare Provider:**

The purpose of this letter is to inform you about the potential risk of myocardial infarction observed with long-term use of alvimopan.

The FDA has determined that a **Risk Evaluation and Mitigation Strategy (REMS)** is necessary to ensure that the benefits of alvimopan outweigh this potential risk by informing/reminding you that alvimopan should only be used short-term (no more than 15 doses) and in a hospital inpatient setting.

On 12/19/2019, the Food and Drug Administration (FDA) approved the Alvimopan REMS, which replaces the E.A.S.E.® ENTEREG® REMS Program.

### **REMS Requirements**

Alvimopan is available only to hospitals that perform bowel resection surgeries and are enrolled in the Alvimopan REMS.

### **Inpatient Hospital Certification**

To become certified, your hospital pharmacy must be enrolled in the Alvimopan REMS before you can prescribe alvimopan.

The Program requires that an authorized representative designated by the hospital pharmacy attests that:

- The Alvimopan REMS Kit has been received by the hospital and that all healthcare providers who are responsible for prescribing, dispensing, or administering alvimopan are educated on the benefits and risks of alvimopan
- The authorized representative understands the risks and benefits of alvimopan and has read the materials in the Alvimopan REMS Kit before alvimopan is dispensed.
- The certified hospital pharmacy has policies and procedures in place to limit the use of alvimopan to no more than 15 doses per patient for administration in the hospital inpatient setting only
- The certified hospital pharmacy will not dispense alvimopan for outpatient use and will not transfer alvimopan to any hospital pharmacy not enrolled with the Alvimopan REMS

- The certified hospital pharmacy must re-certify in the program if the authorized representative changes

Alvimopan, a peripherally acting  $\mu$ -opioid receptor antagonist, is indicated to accelerate the time to upper and lower gastrointestinal (GI) recovery following surgeries that include partial bowel resection with primary anastomosis.

For more information on the Alvimopan REMS visit [www.alvimopanREMS.com](http://www.alvimopanREMS.com).

### **Adverse Events Reporting**

To report suspected adverse reactions contact:

- The Alvimopan REMS at 1-800-278-0340.
- FDA at 1-800-FDA-1088 (1-800-332-1088) or at [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**Please see [alvimopanREMS.com](http://alvimopanREMS.com) for links to the complete Prescribing Information**

# Alvimopan REMS Prescriber and Pharmacist Information Brochure

**Dear Prescriber/Pharmacist:**

On 12/19/2019, the Food and Drug Administration (FDA) approved the Alvimopan Risk Evaluation and Mitigation Strategy (REMS), which replaces the E.A.S.E.® ENTEREG® REMS Program.

Alvimopan is only available to hospital pharmacies that are certified in the Alvimopan REMS. Hospital pharmacies that were not certified in the E.A.S.E.® ENTEREG® REMS Program but would like to dispense alvimopan must certify in the Alvimopan REMS. Visit [www.alvimopanREMS.com](http://www.alvimopanREMS.com) to complete the Alvimopan REMS Hospital Pharmacy Enrollment Form or contact the Alvimopan REMS at 1-800-278-0340.

Updated materials for hospital pharmacies previously enrolled in the E.A.S.E.® ENTEREG® REMS Program are available at the new website [www.alvimopanREMS.com](http://www.alvimopanREMS.com). If your authorized representative has changed, please complete a new enrollment form for continued access to alvimopan.

**\*\*There is no action needed if your hospital pharmacy was previously certified in the E.A.S.E.® ENTEREG® REMS Program\*\***

## **What is the Alvimopan REMS?**

This **R**isk **E**valuation and **M**itigation **S**trategy (REMS) is a strategy to mitigate the potential risk of myocardial infarction associated with long-term use of alvimopan.

The REMS is required by the FDA to ensure that the benefits of alvimopan outweigh this potential risk by informing/reminding healthcare providers that alvimopan should only be used short-term (no more than 15 doses) and in a hospital inpatient setting.

## **How does the Alvimopan REMS work?**

Hospital pharmacies that dispense alvimopan, must become certified in the REMS.

**To become certified, your hospital pharmacy must be enrolled in the Alvimopan REMS before you can prescribe alvimopan.**

## **What are the requirements of the Alvimopan REMS?**

The Program requires that an authorized representative designated by the hospital pharmacy attests that:

- The Alvimopan REMS Kit has been received by the hospital and that all healthcare providers who are responsible for prescribing, dispensing, or administering alvimopan are educated on the benefits and risks of alvimopan
- The authorized representative understands the risks and benefits of alvimopan and has read the materials in the Alvimopan REMS Kit before alvimopan is dispensed.
- The certified hospital pharmacy has policies and procedures in place to limit the use of alvimopan to no more than 15 doses per patient for administration in the hospital inpatient setting only
- The certified hospital pharmacy will not dispense alvimopan for outpatient use and will not transfer alvimopan to any hospital pharmacy not enrolled with the Alvimopan REMS
- The certified hospital pharmacy must re-certify in the program if the authorized representative changes

The Alvimopan REMS Kit includes all REMS materials and a copy of the alvimopan Prescribing Information.

### **How do I order Alvimopan?**

In order to receive alvimopan, your hospital pharmacy must enroll and certify in the Alvimopan REMS. Upon certification:

- Alvimopan can be ordered directly from wholesalers
- Alvimopan will be shipped directly to your inpatient hospital pharmacy by the distributor
- Alvimopan cannot be transferred from a certified to a non-certified hospital pharmacy

### **For More Information:**

In addition, all REMS materials are available on the Alvimopan REMS Program Website at [www.alvimopanREMS.com](http://www.alvimopanREMS.com).

### **Adverse Events Reporting**

To report suspected adverse reactions contact:

- Alvimopan REMS at 1-800-278-0340.
- FDA at 1-800-FDA-1088 (1-800-332-1088) or at [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Please see [alvimopanREMS.com](http://alvimopanREMS.com) for links to the complete Prescribing Information

a peripherally acting  $\mu$ -opioid receptor antagonist

[Important Safety Information](#)

| [Prescribing Information](#)

## What is the Alvimopan REMS (Risk Evaluation and Mitigation Strategy)?

The Alvimopan REMS is a safety program to mitigate **the potential risk of myocardial infarction by:**

- Ensuring that alvimopan will only be used short-term (no more than 15 doses) and in a hospital inpatient setting

**Alvimopan is available only to hospitals that perform bowel resection surgeries and are enrolled in the Alvimopan REMS.**

The REMS is required by the U.S. Food and Drug Administration (FDA) to ensure the benefits of alvimopan outweigh its risks.

## Alvimopan REMS Program Overview

As part of the REMS requirements, an authorized representative designated by the hospital pharmacy attests that:

- The Alvimopan REMS Kit has been received by the hospital and that all healthcare providers who are responsible for prescribing, dispensing, or administering alvimopan are educated on the benefits and risks of alvimopan
- The certified hospital pharmacy has policies and procedures in place to limit the use of alvimopan to no more than 15 doses per patient for administration in the hospital inpatient setting only
- The certified hospital pharmacy will not dispense alvimopan for outpatient use and will not transfer alvimopan to any hospital pharmacy not enrolled with the Alvimopan REMS

Alvimopan, a peripherally acting  $\mu$ -opioid receptor antagonist, is indicated to accelerate the time to upper and lower gastrointestinal (GI) recovery following surgeries that include partial bowel resection with primary anastomosis.

## Adverse Event Reporting

Healthcare professionals should report all suspected adverse events associated with the use of alvimopan.

To report suspected adverse reactions, contact 1-XXX-XXX-XXXX or FDA at 1-800-FDA-1088 (1-800-332-1088) or at [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Alvimopan REMS Kit
<ul style="list-style-type: none"><li>• <a href="#">Alvimopan REMS Program Overview</a></li><li>• <a href="#">Alvimopan REMS Dear Healthcare Provider Letter</a></li><li>• <a href="#">Alvimopan REMS Prescriber and Pharmacist Information Brochure</a></li><li>• <a href="#">Prescribing Information</a></li></ul>
<b>Hospital Pharmacies Enroll Here</b>
<ul style="list-style-type: none"><li>• <a href="#">Alvimopan REMS Hospital Pharmacy Enrollment Form</a></li></ul>

[Prescribing Information](#) | [Legal Notices](#) | [Privacy Statement](#)

[www.alvimopanrems.com](http://www.alvimopanrems.com) | Copyright ©2019 | All rights reserved.

a peripherally acting  $\mu$ -opioid receptor antagonist

[Important Safety Information](#) | [Prescribing Information](#)

## Prescribing Information

TRADE NAME	COMPANY	PHONE NUMBER	INFORMATION LINKS

[Prescribing Information](#) | [Legal Notices](#) | [Privacy Statement](#)

[www.alvimopanrems.com](http://www.alvimopanrems.com) | Copyright ©2019 | All rights reserved.

## What is the Alvimopan REMS (Risk Evaluation and Mitigation Strategy)?

The Alvimopan REMS is a safety program to mitigate **the potential risk of myocardial infarction by:**

- Ensuring that alvimopan will only be used short-term (no more than 15 doses) and in a hospital inpatient setting

**Alvimopan is available only to hospitals that perform bowel resection surgeries and are enrolled in the Alvimopan REMS.**

The REMS is required by the U.S. Food and Drug Administration (FDA) to ensure the benefits of alvimopan outweigh its risks.

## Alvimopan REMS Program Overview

As part of the REMS requirements, an authorized representative designated by the hospital pharmacy attests that:

- The Alvimopan REMS Kit has been received by the hospital and that all healthcare providers who are responsible for prescribing, dispensing, or administering alvimopan are educated on the benefits and risks of alvimopan
- The certified hospital pharmacy has policies and procedures in place to limit the use of alvimopan to no more than 15 doses per patient for administration in the hospital inpatient setting only
- The certified hospital pharmacy will not dispense alvimopan for outpatient use and will not transfer alvimopan to any hospital pharmacy not enrolled with the Alvimopan REMS

Alvimopan, a peripherally acting  $\mu$ -opioid receptor antagonist, is indicated to accelerate the time to upper and lower gastrointestinal (GI) recovery following surgeries that include partial bowel resection with primary anastomosis.

## Adverse Event Reporting

Healthcare professionals should report all suspected adverse events associated with the use of alvimopan.

To report suspected adverse reactions, contact 1-XXX-XXX-XXXX or FDA at 1-800-FDA-1088 (1-800-332-1088) or at [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### Alvimopan REMS Kit

- Alvimopan REMS Program Overview
- Alvimopan REMS Dear Healthcare Provider Letter
- Alvimopan REMS Prescriber and Pharmacist Information Brochure
- Prescribing Information

### Hospital Pharmacies Enroll Here

- Alvimopan REMS Hospital Pharmacy Enrollment Form

# DRAFT

[Prescribing Information](#) | [Legal Notices](#) | [Privacy Statement](#)

[www.alvimopanrems.com](http://www.alvimopanrems.com) | Copyright ©2019 | All rights reserved.

05BMDG

## Prescribing Information

TRADE NAME	COMPANY	PHONE NUMBER	INFORMATION LINKS

# DRAFT

[Prescribing Information](#) | [Legal Notices](#) | [Privacy Statement](#)

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JOYCE A KORVICK  
12/19/2019 04:04:41 PM